biotech stocks

Biotech Stocks Continue To Soar, More Gains To Come

Advertisements

Biotech Stocks Continue To Soar, More Gains To Come

Mott Capital Management, Michael Kramer

Mott Capital’s Reading The Markets

An In-depth Global Macro Premium Stock Market Commentary

In Video Format- See How Michael Dissects The Markets

Premium Subscription Based Membership

Just $200 Per Year – Get Your Free 2 Week Trial

Biotech stocks continue to soar, and Biogen and Gilead had big days on Friday. Biogen jumped by nearly 4 percent, taking shares up $368, after reporting robust result on Thursday. Gilead shares jumped by over 5 percent, to over $85, after getting an upgrade from Jefferies and a price target increase to $95.

We have been talking about these two stocks for some time, and the breakout shouldn’t surprise anyone. It seems like the other day when we were focused on Biogen breaking over $318, and Gilead potentially rising to $82.

There appears to be very little standing in the way from Biogen rising to about $400 from its current level.

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 611 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

 

biogen

Gilead also has very little standing between its current price and a rise to $92 as well, but that, of course, doesn’t mean it happens in a straight line.

gilead

Regeneron shares have moved out of its downtrend for the first time since June of 2017. That could help the stock rise to about $420. We can see in the chart the stock test the downtrend and it bounced. With the strength of the sector, the setup looks good.

regenernon

Alexion shares also look close to a big breakout, and could see a rise to about $145.

alxnAcadia has cleared two big hurdles, first breaking above a multi-month downtrend, and then resistance above $31. Next up a multi-year downtrend around $34, which could send shares to about $40.

Vertex has also seen its shares rise substantially.

vertex

With many of the big biotech stocks coming back and primed for more gains, the sector is likely not finished rising.

Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets

Just $200 Per Year – Get Your Free Trial

Recent Videos:

Dollar Breaking Down, Biotech And Intel Breakout

Why Apple May Not Be Toast Afterall

Why It May Be Time To Get Bullish On Materials As Dollar Plunges

What Everyone Seems To Get Wrong On Netflix

The Long Straddle, Plus Biotech Breakout

Subscriber Mail Bag

Euro’s Big Breakout

Inflation, Tesla Plus So Much More

Predicting The Euro’s Rise 


Free Articles Written By Mike:

Intel’s Massive Breakout Could Fuel Stock’s 25% Rise

Starbucks Stock Price Reflects Perception, Not Reality

Why AMD’s Soaring Stock May See a Sharp Pullback

Why Netflix Is Still Cheap Despite 30% Gain In Three Weeks

Why Micron’s 2018 Stock Gains Won’t Last

Apple’s Stock Outlook Overwhelmingly Bullish, Options Indicate

How Netflix Will Spark The Next Media M&A Wave

Biotech M&A Spree Could Push Sector to New Record Highs

Why Apple’s Suppliers Are Plunging As Mega Tech Thrives

Why Chipmaker Lam Research Is Poised For a Rebound

How a Juno Takeover Could Boost Celgene

Why Ford Could Rise By Nearly 30%

Apple Poised to Gain 14%, Defying Skeptics

Exxon Mobil May Rise 20% on the Back of Surging Oil

We offer daily market commentaries sent directly to your inbox or follow us on Twitter.

Join our 611 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Photo Credit Via Flickr

Michael Kramer and the clients of Mott Capital own shares of ACAD

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2017 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #biotech #stocks #biogen #gilead #acadia #regeneron #vertex #alexion

 

Advertisements